Regentis Biomaterials Ltd. (RGNT) Stock Analysis
Verdict: AVOID
Pre-revenue biotech with a 5.3-month cash runway facing binary clinical risks and high dilution probability to fund GelrinC development.
Investment score: 18/100
Analysis as of
Is Regentis Biomaterials Ltd. stock worth reviewing? The TradeMates thesis
Regentis is a high-risk micro-cap in the capital-intensive medical device sector. With zero revenue, a shrinking (though recently replenished) cash pile of $7.38M, and a massive 2025 net loss of $13.6M, the model sees a high probability of further dilution or insolvency before commercialization.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 5/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Regentis Biomaterials Ltd. opportunities and risks
What speaks for RGNT
- Lead Product GelrinC Potential
What speaks against RGNT
- Severely Limited Cash Runway
Frequently asked questions about Regentis Biomaterials Ltd. (RGNT)
Is RGNT stock a good investment?
The TradeMates model rates Regentis Biomaterials Ltd. as AVOID with an investment score of 18/100. Regentis is a high-risk micro-cap in the capital-intensive medical device sector. With zero revenue, a shrinking (though recently replenished) cash pile of $7.38M, and a massive 2025 net loss of $13.6M, the model sees a high probability of further dilution or insolvency before commercialization. This is algorithmic model output, not personal investment advice.
Is RGNT stock a buy?
The TradeMates model verdict for RGNT is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.